

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No	Ineligible for inclusion	No	No
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Rifapentine 150mg dispersible tablet	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

LTBI: Latent TB Infection

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2025

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 150mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine 300mg	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifapentine/Isoniazid 300mg/300mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine 400/80/150/12.5mg tablet	Yes	Yes	N/A	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

LTBI: Latent TB Infection

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2025